Literature DB >> 8145221

Pseudopeptide inhibitors of Ras farnesyl-protein transferase.

S L Graham1, S J deSolms, E A Giuliani, N E Kohl, S D Mosser, A I Oliff, D L Pompliano, E Rands, M J Breslin, A A Deana.   

Abstract

Inhibitors of Ras farnesyl-protein transferase are described. These are reduced pseudopeptides related to the C-terminal tetrapeptide of the Ras protein that signals farnesylation. Deletion of the carbonyl groups between the first two residues of the tetrapeptides either preserves or improves activity, depending on the peptide sequence. The most potent in vitro enzyme inhibitor described (IC50 = 5 nM) is Cys [psi CH2NH]Ile[psi CH2NH]Phe-Met (3). To obtain compounds able to suppress Ras farnesylation in cell culture, further structural modification to include a homoserine lactone prodrug was required. Compound 18 (Cys[psi CH2NH]Ile[psi CH2NH]Ile-homoserine lactone) reduced the extent of Ras farnesylation by 50% in NIH3T3 fibroblasts in culture at a concentration of 50 microM. Structure-activity studies also led to 12 (Cys[psi CH2NH]Val-Ile-Leu), a potent and selective inhibitor of a related enzyme, the type-I geranylgeranyl protein transferase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145221     DOI: 10.1021/jm00032a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Synthesis of mevalonate- and fluorinated mevalonate prodrugs and their in vitro human plasma stability.

Authors:  Soosung Kang; Mizuki Watanabe; J C Jacobs; Masaya Yamaguchi; Samira Dahesh; Victor Nizet; Thomas S Leyh; Richard B Silverman
Journal:  Eur J Med Chem       Date:  2014-11-22       Impact factor: 6.514

2.  NMR studies of novel inhibitors bound to farnesyl-protein transferase.

Authors:  K S Koblan; J C Culberson; S J Desolms; E A Giuliani; S D Mosser; C A Omer; S M Pitzenberger; M J Bogusky
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

3.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Authors:  G C Prendergast; J P Davide; S J deSolms; E A Giuliani; S L Graham; J B Gibbs; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 4.  Farnesyltransferase inhibitors and anti-Ras therapy.

Authors:  J B Gibbs; N E Kohl; K S Koblan; C A Omer; L Sepp-Lorenzino; N Rosen; N J Anthony; M W Conner; S J deSolms; T M Williams; S L Graham; G D Hartman; A Oliff
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Caged protein prenyltransferase substrates: tools for understanding protein prenylation.

Authors:  Amanda J DeGraw; Michael A Hast; Juhua Xu; Daniel Mullen; Lorena S Beese; George Barany; Mark D Distefano
Journal:  Chem Biol Drug Des       Date:  2008-09       Impact factor: 2.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.